The promoters approached a leading generalist CRA known for large corporate ratings. Unfortunately, the analytical team was less familiar with the specialty chemicals sub-sector. While the company’s numbers were solid, the CRA applied generic manufacturing benchmarks. Key strengths like Long-term contracts with pharma MNCs, High entry barriers due to technology licensing and Export-driven revenue stability were under-appreciated. The CRA issued a BBB– rating, barely investment grade, citing sector cyclicality and “limited scale compared to large chemical players
The company engaged us for a shadow rating exercise to understand the gap. Our analysis concluded that the issue wasn’t with business fundamentals but with CRA selection and sectoral understanding.
EBITDA stability, export contracts, and technology licensing were recognized as rating strengths.
Customer concentration was acknowledged but mitigated by long-term contracts.
Financial flexibility and liquidity metrics were given due weight.
This time, the company was assigned an A– rating, two notches higher than before. The stronger rating enabled them to secure ₹200 crore of term loans at 125 bps lower cost and positioned them favorably for potential IPO